Abiomed AbioCor
This article was originally published in The Gray Sheet
Executive Summary
A humanitarian device exemption will be submitted to FDA by the end of 2003, contingent on patient experiences in the ongoing clinical trial and on FDA approval of a qualifying population, Danvers, Mass.-based firm tells Banc of America Securities conference attendees in Las Vegas March 25. The firm expects to implant eight more AbioCor hearts in the U.S. and Europe this year for a total of 15 (1"The Gray Sheet" March 17, 2003, p. 17)...
You may also be interested in...
Abiomed AB5000 Circulatory Support System Will Aid BVS Blood Pump Line
Abiomed's AB5000 circulatory support system will be incorporated into several cardiac assist devices currently under development
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.